Travere Therapeutics (TVTX) Share-based Compensation (2013 - 2026)

Travere Therapeutics' Share-based Compensation history runs 14 years deep, the most recent figure standing at $16.1 million for Q1 2026.

• Quarterly Share-based Compensation rose 40.5% year-over-year to $16.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.5 million (up 28.14% YoY) and the FY2025 annual result came in at $44.9 million, up 21.55% from the prior year.
• Share-based Compensation was $16.1 million for Q1 2026 at Travere Therapeutics, up from $11.5 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $16.1 million in Q1 2026 and bottomed at $8.0 million in Q3 2024.
• A 5-year average of $10.6 million and a median of $10.6 million in 2025 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2022 — Share-based Compensation surged 73.2% — and 2024, when it declined 29.14%.
• Travere Therapeutics' Share-based Compensation stood at $9.3 million in 2022, then retreated by 12.4% to $8.1 million in 2023, then climbed by 13.14% to $9.2 million in 2024, then gained by 24.42% to $11.5 million in 2025, then surged by 40.84% to $16.1 million in 2026.
• Business Quant data shows TVTX's Share-based Compensation at $16.1 million in Q1 2026, $11.5 million in Q4 2025, and $11.3 million in Q3 2025.